Educational Course on GvHD

The Goal

The goal of the GvHD interactive course is to provide a holistic approach and the latest information on the GvHD treatments using ECP therapy and foster discussion between peers.

Agenda

Download Agenda PDF

Day 1 - 10 March 2025

Arrival of participants

19.45 – 20.00
Meeting at hotel lobby

20.00
Dinner with the faculty

Day 2 - 11 March 2025

09.00 – 09.15
Welcome & introduction - Therakos International Healthcare Stakeholders Engagement

09.15 – 09.30
ECP usage in GvHD, CTCL, HTx, LuTx – New regulation and approved indications - Prof Robert Knobler

09.45 – 10.30
Achieving immune tolerance in GvHD - Prof Thomas Wekerle

10.30 – 10.40
Interactive discussion

10.40 – 10.55
Coffee break

10.55 – 11.25
Acute GvHD: The role of ECP - Prof Hildegard Greinix

• Patient selection for ECP treatment
• Treatment schedule

11.25 – 11.45
Break

11.45 – 12.15
Acute GvHD: The role of ECP - Prof Hildegard Greinix

• Response assessment
• Steroid/ immunosuppressant tapering

12.15 – 12.25
Interactive discussion

12.25 – 13.25
Lunch

13.25 – 13.55
Acute GvHD: The role of ECP - Prof Hildegard Greinix

• NIH Consensus on diagnostic and scoring
• Patient selection for ECP therapy based on organ involvement – The Vienna Experience

13.55 – 14.10
Coffee break

14.10 – 14.50
Acute GvHD: The role of ECP - Prof Hildegard Greinix

• Treatment schedule
• Response assessment including change of co-medication especially steroid / Immunosuppressant taper

14.50 – 15.30
Interactive discussion on challenging patient cases presented by the faculty

15.30 – 16.10
Procedural Aspects of ECP in GvHD – The Vienna Experience - Prof Nina Worel

16.10 – 16.30
Patient cases presented by the HCPs attendees - All

16.30 – 16.40
Final remarks and close

GvHD: Graft versus Host Disease, ECP: Extracorporeal Photopheresis, CTCL: Cutaneous T-cell lymphoma, HTx: Heart Transplantation, LuTx: Lung Transplantation, NIH: National Institutes of Healt

For this course, participants are required to submit one patient case for discussion 15 days in
advance of the session

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals
This information is intended for healthcare professionals based in Europe and the Middle East.

Hosted by

Prof Robert Knobler

Associate Professor of Dermatology, Department of Dermatology, Division for Special & Environmental Dermatology, Medical University of Vienna

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

Explore related courses

Jun 4 - 5, 2025

Educational Course on Treating GvHD – A Patient Focused Approach

University Medical Center (UKE) and University Heart Center (UHZ), Hamburg, Germany

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.